34
Participants
Start Date
December 20, 2021
Primary Completion Date
June 9, 2022
Study Completion Date
June 9, 2022
PC14586
An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).
Parexel Early Phase Clinical Unit - Los Angeles, Glendale
Lead Sponsor
PMV Pharmaceuticals, Inc
INDUSTRY